Given that the cleavage of a specific substrate by PS/γ-secretase may play a role in each disease pathogenesis (e.g., APP in AD and Notch receptors in cancers, etc.), substrate-selective inhibition and/or activation of PS/γ-secretase would be desired for the development of efficient therapeutic strategies. Here, APP is linked to Alzheimer disease.